{"schema_version":"secwatch.filing_event.v1","accession":"0001842952-25-000037","form_type":"8-K","ticker":"CNTX","cik":"0001842952","company_name":"Context Therapeutics Inc.","filed_at":"2025-04-09T23:59:59+00:00","discovered_at":"2026-05-14T18:02:50.095540+00:00","generated_at":"2026-05-23T18:33:30.311071+00:00","sec_items":["7.01","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Context Therapeutics doses first patient in Phase 1 trial of CT-95 bispecific antibody","bullets":["CT-95 is a mesothelin x CD3 T cell engaging bispecific antibody targeting MSLN-expressing cancers.","Second TCE bispecific to enter clinic in 2025 following CTIM-76 (Claudin 6 x CD3) earlier this year.","Phase 1 open-label dose escalation and expansion study for advanced solid tumors (ovarian, pancreatic, lung, mesothelioma).","Initial data for CT-95 Phase 1 trial expected in mid-2026.","CEO Martin Lehr highlights expansion of clinical pipeline and leadership in TCE therapies."],"urls":{"canonical":"https://secwatch.observer/filing/0001842952-25-000037","json":"https://secwatch.observer/filing/0001842952-25-000037.json","markdown":"https://secwatch.observer/filing/0001842952-25-000037.md","text":"https://secwatch.observer/filing/0001842952-25-000037.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1842952/000184295225000037/0001842952-25-000037-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1842952/000184295225000037/cntx-20250409.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-23T18:33:30.311071+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}